F18 Florbetapir (amyvid) cardiac PET/CT imaging for Cardiac Amyloidosis

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Cardiac AmyloidosisF18 Florbetapir (amyvid) cardiac PET/CT imaging - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a chemotherapy regimen can reduce the amount of amyloid protein in the heart of patients with AL amyloidosis.

Eligible Conditions
  • Cardiac Amyloidosis

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 12 months

12 months
Cardiac response
Hematologic response
Patient related outcomes
six months
Relative change in cardiac uptake of 18F florbetapir prior to chemotherapy and after six months of chemotherapy.
twelve months
six minute walk test

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Patients with AL cardiac amyloid
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: F18 Florbetapir (amyvid) cardiac PET/CT imaging · No Placebo Group · Phase 4

Patients with AL cardiac amyloid
Drug
Experimental Group · 1 Intervention: F18 Florbetapir (amyvid) cardiac PET/CT imaging · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
566 Previous Clinical Trials
1,154,158 Total Patients Enrolled
Chris Mueller, MDPrincipal InvestigatorMedical College of Wisconsin

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are a woman of child bearing potential.
References